Zobrazeno 1 - 10
of 29
pro vyhledávání: '"B E Fischer"'
Autor:
Sung Jin An, Shu Ping Lau, Gao Xingyu, B E Fischer, Andrew A. Bettiol, Jinkyoung Yoo, Andrew T. S. Wee, Lie Huang, Frank Watt, Herbert O. Moser, Gyu-Chul Yi, Marian Cholewa
Publikováno v:
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. 254:55-58
The secondary electron emission (SEE) yield of heterostructures of zinc oxide (ZnO) nanoneedles coaxially coated with aluminum nitride (AlN) or gallium nitride (GaN) has been studied using ion and X-ray beams. This paper describes experiments perform
Publikováno v:
Neurochirurgie Scan. :253-254
Publikováno v:
Acta Biotechnologica. 10:355-360
Supernatants of a melanoma cell line were chromatographed on five affinity supports to evaluate and compare purification protocols for isolation of tissue-type plasminogen activator (t-Pa). t-PA was effectively adsorbed quantitatively from cell cultu
Quantitative charge collection measurements have been performed on SOI capacitors using a58N33+ micro beam at 3.6 MeV/u. Collection efficiencies as well as charge sharing effects on adjacent devices through coincidence measurements are reported and d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::928d968b4bd0fc9ba7790077bf628536
https://hal.in2p3.fr/in2p3-00337536
https://hal.in2p3.fr/in2p3-00337536
Autor:
M, Himmelspach, M, Pfleiderer, B E, Fischer, B, Plaimauer, G, Antoine, F G, Falkner, F, Dorner, U, Schlokat
Publikováno v:
Thrombosis research. 97(2)
Factor X/Xa plays a pivotal role in the coagulation cascade and exhibits a therapeutic potential for the treatment of factor X-deficient as well as FVIII and FIX inhibitor patients. This report describes the establishment of Chinese hamster ovary cel
Autor:
B E, Fischer
Publikováno v:
Journal of thrombosis and thrombolysis. 8(3)
Human von Willebrand factor (vWF) produced by recombinant technology offers a new perspective in treatment of von Willebrand disease (vWD). Several limitations connected with plasma-derived vWF concentrates, such as proteolytic degradation during the
Publikováno v:
Thrombosis research. 91(1)
von Willebrand factor (vWF) from normal human plasma was purified and separated into three fractions containing high, medium, and low molecular weight vWF multimers. vWF fractions were tested for (1) vWF-antigen (vWF:Ag); (2) vWF-ristocetin cofactor
Autor:
B E, Fischer, F, Dorner
Publikováno v:
Thrombosis research. 89(3)
Autor:
B. E. Fischer, I. J. LaHaie
Publikováno v:
IEEE Antennas and Propagation Magazine. 55:172-172
Autor:
U, Schlokat, B E, Fischer, S, Herlitschka, G, Antoine, A, Preininger, G, Mohr, M, Himmelspach, O, Kistner, F G, Falkner, F, Dorner
Publikováno v:
Biotechnology and applied biochemistry. 24(3)
Recombinant human von Willebrand Factor (rvWF), a multimeric glycoprotein essential to haemostasis, has been developed as a potential therapeutic agent for treatment of von Willebrand disease (vWD). Permanent Chinese-hamster ovary (CHO)-rvWF cell clo